CA2609985A1 - Modulation des dysfonctionnements de la barriere cellulaire - Google Patents

Modulation des dysfonctionnements de la barriere cellulaire Download PDF

Info

Publication number
CA2609985A1
CA2609985A1 CA002609985A CA2609985A CA2609985A1 CA 2609985 A1 CA2609985 A1 CA 2609985A1 CA 002609985 A CA002609985 A CA 002609985A CA 2609985 A CA2609985 A CA 2609985A CA 2609985 A1 CA2609985 A1 CA 2609985A1
Authority
CA
Canada
Prior art keywords
opioid receptor
opioid
aeruginosa
receptor antagonist
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002609985A
Other languages
English (en)
Inventor
John C. Alverdy
Jonathan Moss
Mark W. Lingen
Patrick A. Singleton
Joe G.N. Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/007892 external-priority patent/WO2006096626A2/fr
Application filed by Individual filed Critical Individual
Publication of CA2609985A1 publication Critical patent/CA2609985A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA002609985A 2005-06-03 2006-06-05 Modulation des dysfonctionnements de la barriere cellulaire Abandoned CA2609985A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US68756805P 2005-06-03 2005-06-03
US60/687,568 2005-06-03
US73100905P 2005-10-28 2005-10-28
US60/731,009 2005-10-28
US76085106P 2006-01-20 2006-01-20
US60/760,851 2006-01-20
USPCT/US2006/07892 2006-03-07
PCT/US2006/007892 WO2006096626A2 (fr) 2005-03-07 2006-03-07 Utilisation d'antagonistes opioides pour l'attenuation de la proliferation et de la migration des cellules endotheliales
PCT/US2006/021604 WO2007053194A2 (fr) 2005-06-03 2006-06-05 Modulation des dysfonctionnements de la barriere cellulaire

Publications (1)

Publication Number Publication Date
CA2609985A1 true CA2609985A1 (fr) 2007-05-10

Family

ID=38006351

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002609985A Abandoned CA2609985A1 (fr) 2005-06-03 2006-06-05 Modulation des dysfonctionnements de la barriere cellulaire

Country Status (3)

Country Link
EP (1) EP1901742A2 (fr)
CA (1) CA2609985A1 (fr)
WO (1) WO2007053194A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2368554T3 (en) 2003-04-08 2015-01-26 Progenics Pharm Inc A pharmaceutical composition comprising methylnaltrexone
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
MX2007010833A (es) 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AU2007240873A1 (en) * 2006-04-19 2007-11-01 Jill P. Smith Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
CA2865661C (fr) 2007-03-29 2016-05-17 Progenics Pharmaceuticals, Inc. Antagonistes de recepteurs opioides peripheriques, et leurs utilisations
SI2565195T1 (sl) 2007-03-29 2015-09-30 Wyeth Llc Periferalni opioidni receptorji in antagonisti in njih uporaba
CN101801979A (zh) 2007-03-29 2010-08-11 普罗热尼奇制药公司 (r)-n-溴化甲基纳曲酮的晶体形式及其用途
BRPI0817804A8 (pt) * 2007-10-05 2017-04-18 Toray Industries Agente terapêutico para melhorar as propriedades da pele compreendendo um derivado de morfinano ou qualquer um de seus sais de adição de ácido farmacologicamente permissíveis como um ingrediente ativo
JP5358587B2 (ja) 2008-02-06 2013-12-04 プロジェニックス・ファーマシューティカルス・インコーポレイテッド (r),(r)−2,2’−ビス−メチルナルトレキソンの製造及び用途
CA2719134C (fr) 2008-03-21 2015-06-30 The University Of Chicago Traitement avec des antagonistes des opioides et des inhibiteurs mtor
US20110250278A1 (en) 2008-07-01 2011-10-13 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
CA2676881C (fr) 2008-09-30 2017-04-25 Wyeth Antagonistes de recepteurs opioides peripheriques, et leurs utilisations
US9504736B2 (en) 2010-09-23 2016-11-29 The Regents Of The University Of California Administration of serine protease inhibitors to the stomach
US10485798B2 (en) 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
WO2015148474A1 (fr) 2014-03-25 2015-10-01 Leading BioSciences, Inc. Compositions pour le traitement de l'autodigestion
WO2024002335A1 (fr) * 2022-06-30 2024-01-04 Shanghai Yuguan Biotech Co., Ltd. Souche bacterienne vivante de pseudomonas sp.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US6384044B1 (en) * 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
US20070059272A1 (en) * 2005-06-03 2007-03-15 The University Of Chicago Modulation of microbial pathogen-host cell interactions

Also Published As

Publication number Publication date
WO2007053194A3 (fr) 2007-08-09
EP1901742A2 (fr) 2008-03-26
WO2007053194A2 (fr) 2007-05-10

Similar Documents

Publication Publication Date Title
US20140142133A1 (en) Modulation of cell barrier dysfunction
CA2609985A1 (fr) Modulation des dysfonctionnements de la barriere cellulaire
AU2012272815B2 (en) Treatment of proteinopathies
US20070059272A1 (en) Modulation of microbial pathogen-host cell interactions
EP2285366B1 (fr) Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
Ye et al. Scutellarin inhibits caspase-11 activation and pyroptosis in macrophages via regulating PKA signaling
US20060210656A1 (en) Synergistic Effects of Nuclear Transcription Factor NF-kB Inhibitors and Anti-Neoplastic Agents
Urbauer et al. Mitochondrial metabolism in the intestinal stem cell niche—sensing and signaling in health and disease
Clark et al. Inhibition of protein kinase C attenuates Pseudomonas aeruginosa elastase–induced epithelial barrier disruption
JP2019513749A (ja) 衛生化及び麻酔用のtrpv4及びtrpa1の小分子二重阻害剤
WO2018023108A1 (fr) Les protéines de garniture et les galectines coopèrent et codirigent l'autophagie et sont utiles dans le traitement de maladies liées à l'autophagie.
US20090186949A1 (en) Method for Treating Endothelial and Epithelial Cell Disorders by Administering High Molecular Weight PEG-Like Compounds
CN103221043A (zh) 用于治疗神经元连接发育障碍的erk抑制剂
Wang et al. Chaperone heat shock protein 70 in nucleus accumbens core: a novel biological target of behavioural sensitization to morphine in rats
WO2019246298A1 (fr) Compositions et procédés pour la réduction ou le traitement de la fibrose
Shimazu et al. (−)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release
US11376233B2 (en) Composition, containing sarpogrelate as active ingredient, for preventing or treating sensorineural hearing loss
KR101057485B1 (ko) 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물
US20210069295A1 (en) Galectins control mtor in response to endomembrane damage and provide a mechanism and target for the treatment of autophagy-related diseases
Whiteside et al. WAY‐318068: a novel, potent and selective noradrenaline re‐uptake inhibitor with activity in rodent models of pain and depression
JP2007504181A (ja) セロトニン再取り込み阻害剤およびロキサピンの併用
TW201529066A (zh) 牛樟芝化合物及其用於治療糖尿病的方法
EP2599488A1 (fr) Vicenin 2 et dérivés associés à utiliser en tant qu'agent antispasmodique et/ou prokinétique
NO20062810L (no) Fast farmasoytisk preparatform
KR20230019387A (ko) 호노키올을 포함하는 조성물 및 이의 내피 기능장애 질환의 예방, 개선 및 치료 용도

Legal Events

Date Code Title Description
FZDE Dead